What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach
PLOS ONE · 24.08.2023 · 18 (8) · e0290290
DOI: 10.1371/journal.pone.0290290 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 24.08.2023. Verfasst von Martin M Monti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of California Los Angeles, Los Angeles, California, United States of America. Hauptthemen laut MEDLINE: Consciousness Disorders, Minimal Clinically Important Difference. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Over the last 30 years, there has been a growing trend in clinical trials towards assessing novel interventions not only against the benchmark of statistical significance, but also with respect to whether they lead to clinically meaningful changes for patients. In the context of Disorders of Consciousness (DOC), despite a growing landscape of experimental interventions, there is no agreed standard as to what counts as a minimal clinically important difference (MCID). In part, this issue springs from the fact that, by definition, DOC patients are either unresponsive (i.e., in a Vegetative State; VS) or non-communicative (i.e., in a Minimally Conscious State; MCS), which renders it impossible to assess any subjective perception of benefit, one of the two core aspects of MCIDs. Here, we develop a novel approach that leverages published, international diagnostic guidelines to establish a probability-based minimal clinically important difference (pMCID), and we apply it to the most validated and frequently used scale in DOC: the Coma Recovery Scale–Revised (CRS-R). This novel method is objective (i.e., based on published criteria for patient diagnosis) and easy to recalculate as the field refines its agreed-upon criteria for diagnosis. We believe this new approach can help clinicians determine whether observed changes in patients’ behavior are clinically important, even when patients cannot communicate their experiences, and can align the landscape of clinical trials in DOC with the practices in other medical fields.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Psychology, University of California Los Angeles, Los Angeles, California, United States of America.
- Department of Neurosurgery, Brain Injury Research Center, University of California Los Angeles, Los Angeles, California, United States of America.
- UCLA-Caltech Medical Scientist Training Program, David Geffen School of Medicine, UCLA, Los Angeles, California, United States of America.
- Department of Neurology, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital and Harvard Medical School Charlestown, Massachusetts, United States of America.
ORCID-Profile: Martin M Monti, Norman M Spivak, Brian L Edlow
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- NICHD NIH HHS
- National Institute of General Medical Sciences
- NIH Office of the Director
- U.S. Department of Defense
- National Institute on Disability, Independent Living, and Rehabilitation Research
- James S. McDonnell Foundation
Zitieren
APA
Monti, M. M., Spivak, N. M., Edlow, B. L., & Bodien, Y. G. (2023). What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach. PLOS ONE, 18(8), e0290290. https://doi.org/10.1371/journal.pone.0290290
Vancouver
Monti MM, Spivak NM, Edlow BL, Bodien YG. What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach. PLOS ONE. 2023;18(8):e0290290. doi:10.1371/journal.pone.0290290
BibTeX
@article{Monti2023,
author = {Monti, Martin M and Spivak, Norman M and Edlow, Brian L and Bodien, Yelena G},
title = {What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {8},
pages = {e0290290},
doi = {10.1371/journal.pone.0290290}
}
EUVIMED